Health Trials

About this trial

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.

Eligibility criteria

Qualifiers

Aged 18 years old and above

Histologically confirmed relapsed refractory FL (Module 1) and LBCL (Module 2) after at least 2 prior lines of therapy

ECOG performance status 0 to 2

Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy

Disqualifiers

Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation

Active CNS involvement by B-NHL

Leukemic presentation of B-NHL

History of a clinically relevant CNS medical condition or pathology that required treatment in the preceding year, is currently symptomatic, or that the treating investigator considers to have the potential to interfere with the evaluation of safety, such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, neurodegenerative disorder including Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis or other severe mental illness.

Trial design

Treatments tested in this trial

  • Surovatamig

Treatment groups

270 Participants
are divided into 2 treatment groups

Locations

94
Australia
Research Site3084, Heidelberg Australia
Research SiteNSW 2217, Kogarah Australia
Research Site2109, Macquarie University Australia
Research Site6009, Nedlands Australia

Sponsors and collaborators

AstraZeneca

Lead sponsor

Source ClinicalTrials.gov